[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100560276":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":35,"responsibleParty":46,"collaborators":30,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":30,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":30,"maxAge":58,"enrollmentInfo":59,"targetDuration":30,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":71,"whyStopped":30,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Seoul National University Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Study group","EXPERIMENTAL","Sequential determination of dose according to previous participant's result and by chance.",[13],"Drug: Sugammadex",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Sugammadex","The starting dose of sugammadex will be 0.5mg\u002Fkg. When the dose for a patient was not effective, the dose for next patient will be increased by 0.5mg\u002Fkg. When the dose was effective, the dose for next patient will be decreased by 0.5mg\u002Fkg or maintained, with a 1:1 of allocation ratio.",[9],[21],"Bridion",[23],{"name":24,"affiliation":5,"role":25},"Sang-Hwan Ji, M.D., Ph.D.","PRINCIPAL_INVESTIGATOR",[27,32],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":31},"CONTACT","+82-2-2072-3661",null,"jsh1@snu.ac.kr",{"name":33,"role":28,"phone":29,"phoneExt":30,"email":34},"Jung-Bin Park, M.D., Ph.D.","jb4001@snu.ac.kr",[36],{"facility":5,"status":30,"city":37,"state":30,"zip":38,"country":39,"countryCode":30,"cosmosGeoPoint":40,"geoPoint":45,"contacts":30},"Seoul","03080","South Korea",{"type":41,"coordinates":42},"Point",[43,44],126.9784,37.566,{"lat":44,"lon":43},{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"SPONSOR_INVESTIGATOR","Sang-Hwan Ji","Clinical Assistant Professor","100560276","phase-2-sugammadex-dose-finding-under-two-years-old-100560276",false,"NCT06575036","Sugammadex Dose Finding Under Two Years Old","Reversal of Rocuronium-induced Neuromuscular Blockade by Sugammadex in Children Younger Than 2 Years Old: a Prospective Dose Finding Study","Inclusion Criteria:\n\n* Childern younger than 2 years old who are scheduled to undergo surgery under general anesthesia\n* American Society of Anesthesiologists Physical Status 1 or 2\n\nExclusion Criteria:\n\n* History of hypersensitivity to rocuronium or any anesthetics\n* Presence of cardiovascular or genitourinary disease\n* Presence of severe renal dysfunction or in need of dialysis\n* Presence of severe hepatic dysfunction or coagualtion disorder\n* Current state of administration of neuromuscular blocking agent on admission to operating room\n* Concurrent use of any medications that affect the activity of neuromuscular blocking agents\n* History of malignant hyperthermia\n* Refusal to enroll in the study by one or more parents\n* Presence of any other reasons that investigator regards inappropriate to enroll in the study.","ALL","23 Months",{"count":60,"type":61},33,"ESTIMATED","INTERVENTIONAL",[64],"PHASE2","This is a prospective dose-finding study of sugammadex for conventional reversal of rocuronium-induced neuromuscular blockade in children under two years of age. This study will explore 50% effective dose and 95% effective dose of sugammadex for reversal of neuromuscular blockade in less than two minutes under biased coin up-and-down method.",[67],"Neuromuscular Blockade",[17,69,70],"Children","Dose-finding study","NOT_YET_RECRUITING","2024-08-27",{"date":74,"type":75},"2024-08-29","ACTUAL",{"date":77,"type":61},"2024-09-15",{"date":79,"type":61},"2025-05-31",{"name":48,"class":6},1]